Asset Details
Do you wish to reserve the book?
Plasma EV phenotype modulation in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Plasma EV phenotype modulation in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor
Do you wish to request the book?
Plasma EV phenotype modulation in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Plasma EV phenotype modulation in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor
2018
Overview
Background: Plasma EVs, a heterogeneous population of vesicles with different origins, have attracted major interest as biomarker source, especially in cancer patients. Besides containing those deriving from tumour cells, the composition and phenotype of plasma EVs might reflect immune status and its modulation in relation to anti-cancer agents. Here we investigated if the EV phenotype associated with changes in routine blood tests and peripheral blood immunophenotype in metastatic renal cell cancer patients (mRCC) undergoing tyrosine kinase inhibitor (TKI) therapy. Methods: After approval by the internal ethical committee, PBMCs and plasma samples were collected from consenting patients at baseline, 3 and 6 months during therapy and stored in liquid N2 and -80°C, respectively. EVs, isolated by two-step differential centrifugation, were evaluated by flow cytometry and western blot. PBMC immunomonitoring was performed by 10-colour cytofluorimetry. Results: EVs contained in F1 (16,500 g) and F2 (118,000 g) expressed CD9 and VLA-2 and both proteins decreased in expression after 3 months TKI administration. The amount of CD9 and VLA-2 in F1 correlated significantly with a decrease of immunosuppressive CD14 +HLA-DRneg myeloid-derived suppressor cells as well as monocyte and platelet counts in samples obtained at 3 months with respect to baseline, detected by flow cytometry of PBMCs and routine blood tests. CD9 and VLA-2 in F1 EVs also correlated inversely with CD3negCD56hi16neg cells, a subset of natural killer cells. This indicates an association of circulating EV phenotype with changes occurring at peripheral blood level in RCC patients receiving TKI. Summary/Conclusion: These preliminary data suggest that plasma EVs may reflect the immune status and the immunomodulating effects occurring during cancer therapies. Additionally, they encourage the rapid development of reliable techniques for the systematic application of body fluid EVs as immune biomarkers of liquid biopsy in cancer. Funding: This work was funded by Italian Ministry of Health grant [GR2011-02351400].
Publisher
John Wiley & Sons, Inc
Subject
